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Abstract
Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and
mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response
of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a
prognostic indicator.
Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF
(n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23),
patients following HTx (n = 85) and healthy controls (n = 30).
Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001;
controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower
(3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation
(40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD
placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1 ng/ml post-HTx
versus 28.2 ± 14 pre-HTx; p < 0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher
galectin-3 levels (20.5 ± 8.8 ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3
(r2 = 0.17, p < 0.0001).
Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading
and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3
might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.
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Background
The syndrome of chronic heart failure (HF) is associated
with increasing morbidity and mortality throughout the
world. As the failing heart deteriorates in function,
ventricular dilatation and hypertrophy compensate for
increased wall stress associated with myocardial in-
flammation and cardiac fibrosis. Proliferating myofi-
broblasts deposit pro-collagen I into the myocardial
matrix which is cross-linked to form collagen I [1–3].
Fibrotic remodeling and associated collagen deposition re-
sults in myocardial tissue heterogeneity and increased
stiffness contributing to a vicious cycle of progressive
cardiac dysfunction [2, 3].
Galectin-3, a paracrine factor secreted by macrophages,
has been identified as a critical participant in the
pathogenesis and progression of cardiac fibrosis and
inflammation [2, 3]. Galectin-3 is secreted in response to
mechanical stress and neurohormonal stimuli and poten-
tiates TGF-β signaling, a critical regulator of cardiac fibro-
sis [2]. Therefore, galectin-3 is a particularly intriguing
biomarker. Unlike current indicators of HF severity, it is
directly implicated in the pathogenesis of cardiac fibrosis.
Recent studies have shown that galectin-3 correlates with
HF severity and may be predictive of clinical outcomes in
HF patients [4–7].
Cardiac fibrosis directly correlates with the degree of
ventricular dysfunction and dilatation as well as with myo-
cardial wall stress. The impact of mechanical unloading
through left ventricular assist device (LVAD) implantation
on myocardial fibrosis is controversial and might be
influenced by the type of LVAD implanted, underlying
cardiomyopathy, and HF duration [8]. Nevertheless, LVAD
implantation has evolved into a standard therapy for pa-
tients with advanced HF, serving either as destination
therapy or as a “bridge-to-transplantation” [9]. Notably,
restoration of cardiac output with LVADs has been shown
to reverse cardiomyocyte hypertrophy and decrease
ventricular end-diastolic dimensions [8, 10].
Interstitial myocardial fibrosis has also been linked to
cardiac remodeling following heart transplantation (HTx)
and in particular to the development of cardiac allograft
vasculopathy (CAV). CAV is a largely immune-mediated
process characterized by diffuse neo-intimal proliferation
leading to coronary artery stenosis, which is a major cause
of morbidity and mortality in patients following HTx with
limited treatment options. Ten percent of HTx recipients
are diagnosed with CAV 1 year post-HTx and more than
50 % have CAV by 10 years post-HTx [11].
We hypothesized that galectin-3 levels correlate with
severity of HF and respond to mechanical unloading
through LVAD placement. Therefore, we analyzed galectin-
3 levels in patients with various degrees of HF, before and
after mechanical unloading through LVAD implantation,
and following HTx.
Methods
Study design and patient population
We included 118 patients with HF in this study. Fifty-five
patients had stable HF defined as NYHA Class of I-IIIA.
Sixty-three patients had severe HF (NYHA Class IIIB-IV),
and 57 of these patients received LVADs either as a
bridge-to-transplantation or destination therapy. Of the
patients who received LVADs, 52 received a Heartmate II
axial flow LVAD (Thoratec, Pleasanton, CA) and 5 re-
ceived a Heartware centrifugal flow LVAD (Heartware,
Framingham, MA). Follow-up samples were collected
after device implantation (17 patients at 3 months post-
LVAD and 14 patients at 6 months). Of the 57 patients
who received LVADs, 14 had their LVADs explanted dur-
ing HTx. Nine additional patients were recruited at the
time of LVAD explantation, creating a LVAD-explantation
cohort of 23 patients. In addition, 85 patients following
HTx (1 month to 20 years post-HTx) were analyzed. All
patients were evaluated for the presence of CAV by in-
vasive coronary angiogram. CAV was defined according
to the ISHLT CAV grading system. Twenty-three pa-
tients were diagnosed with CAV and 62 patients
showed no sign of CAV. There were 30 healthy subjects
who served as controls and were selected to match the
age and gender of patients in the other cohorts. Pa-
tients with significant medical history, including but
not limited to heart disease, lung disease, kidney dis-
ease, liver disease, cancer, stroke, diabetes, and thyroid
disorders were excluded.
This is a retrospective study utilizing samples obtained
from HF patients at Columbia University, some of whom
underwent LVAD implantation or heart transplantation.
All blood samples were immediately processed by centri-
fugation for collection of plasma and serum. Plasma was
transferred to 1 mL cryotubes and stored at −80 °C until
analysis. Clinical, laboratory, and outcome information
was collected from patient medical records. All patients
were recruited from the clinics or inpatient services at
Columbia University Medical Center. The study protocol
was approved by the Institutional Review Board at
Columbia University Medical Center and written in-
formed consent was obtained from all individuals prior
to inclusion into the study.
Galectin-3 measurements
Plasma galectin-3 was measured using a commercially
available ELISA assay (Galectin-3 Assay, BG Medicine,
Waltham, MA), which has a measuring range of 1.4 to
94.8 ng/mL and coefficient of variation of 10.4 %, with
no significant cross reactivity. Samples were run on a
SpectraMax 250 microplate reader (Molecular Devices,
Sunnyvale, CA). Calibration of the assay was performed
according to the manufacturer’s recommendations and
values were normalized to a standard curve.
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Statistical analyses
Data were presented as mean ± standard deviation. Com-
parisons among all groups were performed using ANOVA
or Students’s t-test as appropriate, as well as correlational
analysis using Spearman’s correlation. ROC analysis was
used to identify galectin-3 levels predictive of poor
outcome and event rates were calculated using the
Kaplan-Meier method. Probability values of p < 0.05 were
considered to be statistically significant.
Results
Galectin-3 levels in patients with different degrees of heart
Failure
Galectin-3 levels were measured in 55 patients with
stable HF (defined as NYHA Class I-IIIA), 63 patients
with severe HF (NYHA Class IIIB-IV) and 30 healthy
controls. Baseline demographics are listed in Table 1. Pa-
tients with severe HF had lower LVEF and higher BNP
levels compared to those with stable HF. Patients with
severe HF were also less likely to be hypertensive, and
more likely to have concurrent kidney disease.
Patients with stable HF had higher galectin-3 levels
compared to healthy controls (19.7 ± 13 versus 13.2 ±
9 ng/ml; p = 0.02). Galectin-3 levels were higher in pa-
tients with severe HF compared to patients with stable
HF (28.2 ± 14 ng/ml in severe HF; p = 0.001) (Fig. 1a).
Galectin-3 levels correlated with severity of HF as de-
fined by NYHA class (p = 0.001) and creatinine (R2 = 0.166;
p < 0.0001) (Fig. 1b). There was no correlation between
galectin-3 levels and BNP (R2 = 0.032; p = 0.09) or LVEF
(R2 = 0.0095; p = 0.30) (Fig. 1c-d)
Dynamics of galectin-3 levels following LVAD
implantation
Of the 57 patients who received LVADs, 17 patients had
follow-up levels measured at 3-months, 14 patients had
Table 1 Demographic data of patients with HF
Controls (n = 30) Stable HF (n = 55) p-value* Severe HF (n = 63) p-value†
Galectin-3 (ng/ml) 13.2 ± 9 19.7 ± 13 0.02 28.2 ± 14 0.001
Age (yrs) 52 ± 8 59 ± 10 0.001 62 ± 11 NS
Gender (% male) 73 % 76 % NS 92 % 0.01
BMI (kg/m2) 27 ± 5 28 ± 4 NS 28 ± 5 NS
Etiology (%)
Ischemic - 45 % - 56 % NS
Dilated - 42 % - 40 %
Hypertrophy - 2 % - 1 %
Unspecified - 11 % - 3 %
NYHA Class - 2.3 ± 0.8 - 3.7 ± 0.4 <0.0001
LVEF (%) - 24 ± 9 - 18 ± 5 <0.0001
BNP (ng/mol) - 707 ± 762 - 1384 ± 1097 0.001
Comorbidities
Hypertension 13.3 % 61.8 % <0.0001 49.2 % 0.007
Previous MIa 0 % 41.8 % <0.0001 38.1 % NS
Hyperlipidemia 23.3 % 50.9 % 0.0005 41.2 % NS
Diabetes 0 % 30.9 % 0.0001 39.7 % NS
Kidney Disease 0 % 12.7 % 0.02 38.1 % 0.007
COPDb 0 % 9.1 % 0.04 14.3 % NS
Smoker 6.7 % 5.5 % NS 1.6 % NS
Lab Values
WBCc (x103/μL) - 7.1 ± 2 - 8.8 ± 3 0.001
Hctd (g/dL) - 39 ± 4 - 32 ± 10 <0.0001
Nae (mEq/L) 145 ± 10 137 ± 3 <0.0001 135 ± 3 0.0008
Creatf (mg/dL) 1.0 ± 0.3 1.3 ± 0.9 NS 1.5 ± 0.5 NS
T-Bilig (mg/dL) 0.5 ± 0.2 0.7 ± 0.4 0.007 1.6 ± 1.4 0.0004
Albumin (g/dL) 4.9 ± 0.4 4.3 ± 0.4 <0.0001 3.6 ± 0.5 <0.0001
*p value versus Controls †p value versus Stable HF
aMI myocardial infarction, bCOPD chronic obstructive pulmonary disease, cWBC white blood count, dHct hematocrit, eNa sodium, fCrea creatinine, gT-Bili total bilirubin
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follow-up levels measured at 6-months and 14 patients
had levels measured at the time of LVAD explantation.
An additional 9 patients were analyzed at the time of ex-
plantation. On average, patients who underwent LVAD
explantation had been on LVAD support for 277 ±
223 days. Demographic information of this cohort at
baseline and during follow-up is listed in Table 2.
Hemodynamic unloading was associated with lower
BNP levels following LVAD treatment (1378 ± 1084 versus
737 ± 470 pmol/L at explant, p = 0.01). Further, LVAD
support was associated with improvement in echocar-
diographic parameters with a smaller left ventricular
end-diastolic diameter (LVEDD) and left atrial (LA)
diameter (LVEDD: 67.2 ± 10 versus 58.4 ± 10 mm at
explant, p = 0.012; LA: 50.1 ± 60 versus 44.3 ± 70 mm
at explant, p = 0.004). There was also a trend towards
smaller left ventricular end systolic diameter (LVESD:
60.8 ± 11 versus 52.8 ± 14 mm, p = 0.1). There was no
significant change in aortic root diameter (3.4 ± 0.4 vs.
3.5 ± 0.3 cm; p = 0.39).
Following LVAD implantation, a downward trend in
galectin-3 levels was noted, although it did not reach sig-
nificance (29.2 ± 14 ng/ml at implantation versus 23.7 ±
8 ng/ml 3 months post-implantation; p = 0.13) (Fig. 2a).
Six months post-implantation, the average galectin-3
level was 21.7 ± 9 ng/ml (versus 29.2 ± 14 ng/ml at
implantation, p = 0.06). Of the 17 patients who were
evaluated 3 months following implantation, 64.7 % had
lower galectin-3 levels compared to implantation. For
these 17 patients, the mean galectin-3 level was lower at
3 months, though this difference was not significant
(23.7 ± 8 at 3 months versus 29.0 ± 14.5 ng/ml at implant-
ation, p = 0.2). Of the 14 patients who were evaluated at
6 months, 57.1 % had lower galectin-3 levels compared
implantation. Again, the mean was lower at 6 months for
these patients than at the time of implantation (21.7 ±
9 ng/ml at 6 months versus 28.1 ± 15 ng/ml at implant-
ation, p = 0.18).
Surprisingly, galectin-3 levels were significantly
higher at the time of LVAD explantation (40.4 ± 19 at
explant versus 29.2 ± 14 ng/ml at the time of implant-
ation, p = 0.005). Of the 23 explanted patients, 14
patients were evaluated both at implantation and ex-
plantation, allowing for direct comparison of values. Of
these 14 patients, 13 (92.9 %) had elevated galectin-3
levels at the time of explantation as compared to time
of implantation (Fig. 2b). Galectin-3 was significantly
higher at the time of explantation compared to im-
plantation in these 14 patients. (40.6 ± 17 versus 20.8 ±
5 ng/ml, p = 0.0002).
Prognostic impact of galectin-3 levels on clinical
outcomes
Patients with severe HF who died during the study had
significantly higher galectin-3 levels than those who were
still alive (48.6 ± 16 versus 28.2 ± 14 ng/ml, p = 0.02). To
Fig. 1 Galectin-3 levels correlate with severity of HF. a Stepwise increase in mean galectin-3 levels in patients with increasing severity of HF
(*p < 0.05; ***p < 0.001). b Galectin-3 levels correlate with creatinine levels in patients with HF and controls. c Lack of correlation of galectin-3 with
mean LVEF. d Lack of correlation of galectin-3 with BNP
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Table 2 Demographic data of patients undergoing LVAD placement
LVAD Implant (n = 57) 3 Months
Post-LVAD (n = 17)
p-value* 6 Months




Galectin-3 (ng/ml) 29.2 ± 14 23.7 ± 8 NS 21.7 ± 9 NS 40.4 ± 19 0.005
Age (yrs) 63 ± 10 65 ± 9 NS 60 ± 12 NS 63 ± 8 NS
Gender (% male) 91 % 100 % NS 93 % NS 87 % NS
BMI (kg/m2) 28 ± 5 28 ± 4 NS 28 ± 5 NS 26 ± 4 NS
Etiology (%)
Ischemic 56 % 65 % NS 64 % NS 65 % NS
Dilated 39 % 35 % 36 % 35 %
Hypertrophy 2 % 0 % 0 % 0 %
Unspecified 3 % 0 % 0 % 0 %
BNP (ng/mol) 1378 ± 1084 - - - - 737 ± 470 0.01
LVAD Type (%)
Continuous 91 % 100 % NS 82 % NS 100 % NS
Pulsatile 9 % 0 % 18 % 0 %
Comorbidities
Hypertension 54.4 % 64.7 % NS 42.9 % NS 47.8 % NS
Previous MIa 42.1 % 47.1 % NS 35.7 % NS 52.2 % NS
Hyperlipidemia 45.6 % 52.9 % NS 42.9 % NS 47.8 % NS
Diabetes 39.7 % 52.9 % NS 21.4 % NS 30.4 % NS
Kidney Disease 38.1 % 64.7 % NS 35.7 % NS 43.5 % NS
COPDb 15.8 % 29.4 % NS 7.1 % NS 17.4 % NS
Smoker 1.8 % 0 % NS 0 % NS 4.4 % NS
Lab Values
WBCc (x103/μL) 9.0 ± 3 9.4 ± 4 NS 8.9 ± 4 NS 9.3 ± 4 NS
Hctd (g/dL) 31 ± 10 32 ± 9 NS 35 ± 7 NS 30 ± 4 NS
Nae (mEq/L) 136 ± 4 136 ± 4 NS 135 ± 4 NS 137 ± 4 NS
Creaf (mg/dL) 1.5 ± 0.5 1.6 ± 0.4 NS 1.4 ± 0.5 NS 1.3 ± 0.6 NS
T-Bilig (mg/dL) 1.6 ± 1.4 1.3 ± 0.4 NS 1.5 ± 1.7 NS 1.2 ± 0.9 NS
Albumin (g/dL) 3.6 ± 0.5 3.5 ± 0.5 NS 3.8 ± 0.4 NS 3.3 ± 0.5 0.02
*p value versus LVAD Implant
aMI myocardial infarction, bCOPD chronic obstructive pulmonary disease, cWBC white blood count, dHct hematocrit, eNa sodium, fCrea creatinine, gT-Bili total bilirubin
Fig. 2 Changes in galectin-3 levels following LVAD implantation. a Galectin-3 levels show a trend towards lower levels early after LVAD placement
at 3 and 6 months but were higher in patients at the time of LVAD explanation (**p < 0.01). b Dynamics of 14 paired patient samples time of
implantation to time of explantation
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determine if galectin-3 could be used as a prognostic
indicator in this cohort, we performed an ROC curve
analysis of patients with severe HF and determined that
a pre-operative galectin-3 cutoff value of 35.4 ng/ml pre-
dicted higher mortality following LVAD placement
(66.7 % specificity, 84.2 % sensitivity, p = 0.025) (Fig. 3a).
Given this, we chose a clinically useful cutoff of 30 ng/ml
and dichotomized patients based on this level. Galectin-
3 levels greater than 30 ng/ml at the time of LVAD im-
plantation are associated with poor survival at 2 years
post implantation (p = 0.009) (Fig. 3b). 2 years following
implantation, 95.0 % of patients with galectin-3 levels
<30 ng/ml at the time of LVAD implantation were still
alive, compared to 76.5 % of patients with galectin-3
levels >30 ng/ml at implantation.
Galectin-3 levels decrease following heart transplantation
We analyzed galectin-3 levels in 85 patients following
HTx (1 month-20 years post-HTx, Table 3). On average,
galectin-3 levels were measured 5.4 ± 0.64 years post-HTx.
Galectin-3 levels were lower following HTx compared to
in patients with severe HF (17.8 ± 7.3 post-HTx versus
28.2 ± 14 ng/ml in severe HF, p < 0.0001) (Fig. 4a). How-
ever, galectin-3 levels post-HTx were found to be higher
compared to healthy controls (17.8 ± 7.3 versus 13.2 ±
9.4 ng/ml in controls, p = 0.002) and comparable to levels
in patients with stable HF (19.7 ± 13.0 ng/ml in stable HF,
p = 0.44). No correlation was found between galectin
levels and time since HTx.
Patients following HTx were sub-classified with regard
to the occurrence of CAV according to the ISHLT CAV
grading system (CAV Grade 0: n = 62, Grade 1–3: n = 23).
Galectin-3 levels were higher in patients with evidence of
CAV compared to those without CAV (20.5 ± 8.9 versus
16.8 ± 6.3 ng/mL without CAV, p = 0.03) (Fig. 4b).
Spearman correlational analysis revealed a correlation
between galectin-3 levels and the occurrence of CAV
(r2 = 0.17, p < 0.0001).
Discussion
In this study, we measured galectin-3 levels in patients
with various stages of HF, following LVAD support, and
after HTx. Galectin-3 was higher in advanced stages of HF
compared to controls, was lower post-LVAD, but in-
creased at the time of LVAD explantation. Baseline
galectin-3 greater than 30 ng/mL predicted poor outcome
following LVAD placement. Patients following HTx on
average have lower galectin-3 levels, but levels are higher
in the presence of CAV.
Interest in galectin-3 as a potential marker of the se-
verity and outcome of HF has increased with evidence
that it is involved in the pathogenesis of cardiac fibrosis
and HF progression. By stimulating TGF-β, galectin-3
potentiates collagen deposition and extracellular matrix
turnover, leading to an increased proportion of stiffer
collagen I in the failing myocardium [12–14]. Prior stud-
ies have identified galectin-3 as the most robustly up-
regulated protein in models of cardiac hypertrophy and
left ventricular dysfunction, and mice with a galectin-3
gene deletion develop myocardial hypertrophy without
cardiac dysfunction and fibrosis [5, 15]. Consistent with
these animal models, galectin-3 levels have consistently
been shown to correlate with disease severity and NYHA
class in HF [3, 6, 7].
Our results confirmed that galectin-3 levels correlated
with the severity of HF, and levels in healthy subjects were
Fig. 3 Pre-implant galectin-3 levels predict postoperative mortality following LVAD placement. a ROC analysis of patients with severe HF revealed
a cut-off value of 35.4 ng/ml as predictive of poor outcome (sensitivity of 66.7 % and specificity of 84.2 %, p = 0.025). b Patients with galectin-3
level >30 ng/ml at the time of LVAD implantation showed higher mortality during the first 2 years post-LVAD implantation (log rank p = 0.0086)
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consistent with prior reports defining the normal range as
less than 18 ng/ml [7]. Although BNP and LVEF are often
used to measure HF severity, we found that galectin-3
levels were not directly associated with these parameters,
though some prior studies have shown correlation
between galectin-3 and these measures. [16]. Because the
majority of HF patients in our study had ischemic HF, our
results should only be applied to this population, although
others have shown comparable levels of galectin-3 in
patients with ischemic and non-ischemic HF [5].
Table 3 Demographic data of patients following HTx
Control (n = 30) Post-HTx (n = 85) p-value* No CAV (n = 62) CAV (n = 23) p-value†
Galectin-3 (ng/ml) 13.2 ± 9 17.8 ± 7 0.002 16.8 ± 6 20.5 ± 9 0.03
Age (yrs) 52 ± 8 55 ± 14 NS 54 ± 14 58 ± 13 NS
Gender (% male) 73 % 71 % NS 80 % 81 % 0.02
BMI (kg/m2) 27 ± 5 29 ± 6 NS 29 ± 6 28 ± 5 NS
Etiology (%)
Ischemic - 32 % - 54 % 45 % NS
Dilated - 43 % 31 % 45 %
Hypertrophy - 2 % 0 % 3 %
Unspecified - 13 % 15 % 7 %
LVEF (%) - 59 ± 8 60 ± 8 55 ± 8 <0.0001
Years post-HTx - 5.4 ± 0.6 - 5.2 ± 1.2 5.5 ± 1.0 NS
Comorbidities
Hypertension 13.3 % 61.7 % <0.0001 55.6 % 67.7 % NS
Prior MIa 0 % 32.6 % 0.0003 25.9 % 45.2 % NS
Hyperlipidemia 23.3 % 48.3 % 0.02 50.0 % 45.2 % NS
Diabetes 0 % 49.4 % <0.0001 50.0 % 41.9 % NS
Kidney Disease 0 % 38.2 % <0.0001 31.5 % 48.4 % NS
COPDb 0 % 6.7 % NS 7.4 % 3.2 % NS
Smoker 6.7 % 5.6 % NS 7.4 % 3.2 % NS
Lab Values
WBCc (x103/μL) 7.6 ± 5 6.8 ± 2.3 NS 6.9 ± 2.2 6.6 ± 2.6 NS
Nad (mEq/L) 145 ± 10 139 ± 2 <0.0001 139 ± 2 140 ± 2 NS
Creae (mg/dL) 1.0 ± 0.3 1.5 ± 0.6 <0.0001 1.5 ± 0.5 1.7 ± 0.6 NS
T-Bilig (mg/dL) 0.5 ± 0.2 0.7 ± 0.4 0.01 0.7 ± 0.3 0.8 ± 0.4 NS
Albumin (g/dL) 4.9 ± 0.4 4.3 ± 0.4 <0.0001 4.3 ± 0.4 4.2 ± 0.5 0.05
*p value versus controls; †p value versus no CAV
aMI myocardial infarction, bCOPD chronic obstructive pulmonary disease, cWBC white blood count, eNa sodium, fCrea creatinine; gT-Bili total bilirubi006E
Fig. 4 Changes in galectin-3 levels following HTx. a Levels of galectin-3 are higher in patients with HF and near normal levels in patients following
HTx. b Higher circulating levels of galectin-3 following HTx and in the presence of CAV (*p < 0.05; **p < 0.001; ****p < 0.0001)
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Galectin-3 levels with LVAD support
That galectin-3 levels may initially decrease after LVAD
implantation but were significantly increased at explant-
ation offers interesting insight into the pathologic
changes that occur with mechanical support. Evidence
regarding changes in fibrosis following LVAD implant-
ation have been conflicting [17]. Our group previously
demonstrated decreased ECM turnover with reduced
levels of circulating and myocardial metalloproteinases
following LVAD placement [18]. Similarly, others have
shown decreased myocardial collagen content in LVAD-
supported patients [19, 20]. However, others have shown
an increase in collagen deposition and an associated in-
crease in myocardial stiffness [10, 21, 22].
Only one recent study analyzed changes in galectin-3
levels in patients undergoing LVAD implantation. Milt-
ing et al. found that 30 days post-implantation, ECM
turnover defined by changes in levels of matrix metallo-
proteinases and their tissue inhibitors increased, but
galectin-3 levels remained the same [23]. Our average
length of LVAD treatment of 277 days is longer than in
the study by Milting et al., which may explain why we
were able to detect an increase in galectin-3 levels.
The dynamics of galectin-3 levels following LVAD im-
plantation may be indicative of the complicated changes
in myocardial structure and fibrosis, and further studies
are necessary to more clearly elucidate these fluctuations
in galectin-3 levels. Because galectin-3 is secreted in re-
sponse to mechanical stress, decreased expression shortly
after device implantation may be explained by ventricular
unloading. However, elevated levels at explantation may
indicate that prolonged mechanical support leads to an
increase in inflammation and cardiac fibrosis. This is
consistent with the results of Maybaum et al., who
found that although LVEF significantly improved after
LVAD implantation in almost all patients, longer dur-
ation of LVAD support appeared to deleteriously affect
LV function [24]. Pathologic studies should be con-
ducted to correlate galectin-3 levels with the amount of
fibrosis as well as cardiac macrophage content and acti-
vation. The specific signals for increasing fibrosis after
LVAD placement have not yet been fully elucidated, but
the identification and reversal of this pro-fibrotic signal
could assist to better define the potential of temporary
LVAD placement as a “bridge to recovery” intervention
in certain patients with advanced HF.
Adding to the value of galectin-3 is its potential use as
a predictor of poor outcome in patients with HF. Van
Kimmenade et al. found galectin-3 levels to be prognos-
tic of adverse outcomes over 60 days [5]. Galectin-3 has
also been shown to be an independent predictor of mor-
tality in patients with NYHA class III-IV HF and in the
general population, with levels >25.9 ng/ml shown to be
predictive of a rapid progression of HF [3, 6, 7]. Adding
to these findings, galectin-3 levels were predictive of sur-
vival in our cohort of patients undergoing LVAD place-
ment, with plasma levels greater than 30 ng/ml at the time
of implantation associated with greater mortality. Of note,
although patients with galectin-3 levels >30 ng/ml were of
similar age, NYHA Class, and had similar duration of HF
and BNP levels than those with galectin-3 levels <30 ng//
ml, patients with higher galectin-3 levels did have higher
creatinine levels. It is possible, therefore, that some of the
increased risk seen was due to impaired renal function.
However, another study found that levels were a univariate
but not independent risk factor for death in patients under-
going LVAD implantation [25]. These results indicate that
this predictive value may be applicable to the subset of HF
patients undergoing LVAD implantation, providing import-
ant prognostic information that may be used for patient se-
lection and for stratifying high-risk patients.
Galectin-3 levels following heart transplantation
We found that following HTx, the average galectin-3
level was significantly lower than in patients with severe
HF. This decrease was expected with the replacement of
the failing heart, but notably galectin-3 values did not
return to normal levels; galectin-3 levels in transplanted
patients were comparable to levels in patients with
stable HF. Higher galectin-3 levels post-HTx might be
related to cardiomyocyte hypertrophy and myocardial fi-
brosis after HTx but, of note, elevated galectin-3 levels
are not related to the time period since HTx. No other
study has analyzed trends in galectin-3 levels following
HTx, but prior studies have shown that fibrosis increases
within 2 months after HTx with little change over the sub-
sequent 5–6 years [26]. Another explanation for dynamics
in galectin-3 levels following HTx may be the use of anti-
inflammatory agents to prevent rejection; as galectin-3 is
an inflammatory factor released by macrophages, and its
expression may be modified by this external variable.
As many as half of transplant patients will show angio-
graphic evidence of CAV 5–15 years after HTx, account-
ing for 30–50 % of late graft attrition [27, 28]. Given this
high prevalence and mortality, identification of CAV is
important. However, diagnosis is limited by the lack of
clinical symptoms of ischemia in the denervated allograft
as well as limitations inherent in coronary angiography,
which is a relatively insensitive study and frequently un-
derestimates the severity and presence of CAV [29].
CAV is characterized by intimal luminal narrowing due
to a fibrotic process, with a high expression of TGF-β and
macrophage markers in the intima [30]. T-cells and mac-
rophages have been shown to modulate the pathogenesis
of CAV with a specific role for macrophages regulating
the fibrotic response, and vascular fibrosis after HTx has
been associated with more severe CAV and poor event-
free survival rates [31].
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Our analysis revealed a significant difference in galectin-
3 levels between patients with and without CAV, and
higher levels in patients with more severe degrees of CAV.
Given the importance of fibrosis in CAV pathogenesis and
the implication of macrophages in its development,
galectin-3 may serve as a useful marker of CAV severity
of. Further studies are necessary to better elucidate
whether or not galectin-3 could be used as a screening
tool in the diagnosis of CAV in high-risk patients, poten-
tially linking this novel biomarker to active fibrotic pro-
cesses and signaling in the cardiac allograft.
Of note, our study is limited by its retrospective obser-
vational nature with a limited number of patients from a
single center. Larger, prospective studies should be done
to better elucidate the value of galectin-3 as a predictive
biomarker and its ability to stratify risk in HF patients,
and future studies would benefit from including patho-
logic analysis in addition to serologic. Additionally, not all
of the LVAD patients had consistent follow-up and 14 of
the patients in the explant cohort did not have implant
values available, which may have affected the results of the
study and may represent a bias towards patients feeling
well enough to come to the study visit. The small number
of patients also limited our ability to correct for con-
founders such as age, and renal function when assessing
the predictive value of galectin-3. We do not have baseline
pre-HTx values for patients in the transplant cohort,
limiting the direct comparison to the severe HF cohort.
Additionally there are a relatively small number of pa-
tients in the CAV subgroups of post-HTx patients.
Conclusions
Our results indicate that galectin-3 may serve as a useful
biomarker for evaluating the severity and outcomes in HF
and in patients undergoing LVAD implantation. Galectin-3
is an intriguing biomarker due to its relation to cardiac in-
flammation and fibrosis and, unlike BNP levels, galectin-3
values are not drastically changed by acute cardiac volume
or pressure overload. Its role in patients following HTx
needs further analysis in larger studies.
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